Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.71
2% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $15.2M | $35.1M | $82.8M | $84.1M | $14.5M | $12.7M | $10.8M |
| Cost of revenue | $6.4M | $11.1M | $20.4M | $43.6M | $31.2M | $7.5M | $3.9M | $4.0M |
| Gross profit | $1.3M | $4.1M | $14.7M | $39.2M | $52.9M | $7.1M | $8.8M | $6.8M |
| Gross margin | 17.2% | 26.7% | 41.8% | 47.4% | 62.9% | 48.6% | 69.1% | 62.9% |
| R&D | $0 | $0 | $0 | $12.9M | $18.3M | $11.0M | $6.6M | $4.6M |
| Operating income | −$10.7M | −$13.6M | −$20.0M | −$14.9M | −$19.0M | −$43.2M | −$20.7M | −$17.5M |
| EBITDA | −$9.9M | −$13.4M | −$21.8M | −$14.2M | −$24.7M | −$42.4M | −$14.4M | −$22.6M |
| Net income | −$13.6M | −$14.2M | −$25.7M | −$22.7M | −$37.1M | −$51.6M | −$27.9M | −$25.5M |
| Net margin | -176.3% | -93.6% | -73.1% | -27.4% | -44.1% | -355.3% | -219.1% | -235.0% |
| EPS (diluted) | -5.94 | -5.34 | -9.56 | -7.96 | -11.95 | -13.30 | -5.99 | -5.49 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $22M | $-2.32 | $-2.32–$-2.32 | 1 |
| 2027 | $41M | $-1.23 | $-1.23–$-1.23 | 1 |
| 2028 | $66M | $-0.43 | $-0.43–$-0.43 | 1 |
| 2029 | $98M | $0.14 | $0.14–$0.14 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds OTRK.
No tracked institution reports a position in OTRK as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-09-23 | 1-for-15reverse |
| 2023-07-28 | 1-for-6reverse |
No one on the platform has traded OTRK yet.
| $115M |
| — |
| PHGEBiomX Inc. | $0.36 | -9.25% | $572091 | — |
| PHIOPhio Pharmaceuticals Corp. | $0.98 | +1.55% | $11M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 23.7× historical median P/S.
Fair value ≈ $62.63 · price $0.06 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@laste_rounde It’s like the good old days of $CATS.X and $OTRK
View on StockTwits ↗$OTRK Crazy. And I believed in that shit and lost so much money :( @lever_age
View on StockTwits ↗@NatesNotes $OTRK chart for reference for all of you. Sitting at all time lows of 0.06 right now. From 8,990 in 2020 to 0.06 now. A great long 😂
View on StockTwits ↗$OTRK $OTRKP RIP. Bankruptcy, no value left: https://www.bankruptcyobserver.com/bankruptcy-case/ontrak
View on StockTwits ↗@stonks508 @lever_age It's all about assets vs liabilities. The time is ticking, 25th of August is the day they can redeem those preferred shares the earliest. Nobody knows what they are going to do. They will need to file something. Voluntarily chapter 11 or 7 is imminent or merger/acquisition. Any assets left after paying off debt to Acuitas and administrative fees will be paid to preferred holders. Anything above $0.02/share is a win. I calculated a deduction cash burn of $8m and an administrative fee with 14% of assets and came out with $1.25/share left to distribute for preferreds. $OTRKP $OTRK
View on StockTwits ↗$OTRK David Michery and Todd Ault must be a part of this shenanigans also $BINI $AULT
View on StockTwits ↗I've never been so happy to see one of stocks go to zero than $otrk $otrkp.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.